Trending...
- Lake Norman Philharmonic - Free Community Concert
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
WEST CHESTER, Pa., Sept. 16, 2021 /PRNewswire/ -- VESTECK, Inc., an early-stage medical device company, is pleased to announce the additional close of funds totaling >$5.2M of Series A financing, which includes conversion of all existing convertible notes.
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
More on The PennZone
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
More on The PennZone
- Ten Ten Ten Awards Provisional Certification to Cara AI for Home-Based Health Assessments
- IDI Consulting Partners with the American Heart Association to Advance Heart Health Awareness
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Diversity Committee
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
0 Comments
Latest on The PennZone
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- New Bethany's 35th Annual Souper Day to Spotlight Connection Between Health, Hunger and Housing
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Mandeville Pests May Pose Serious Health Risks for Your Family
- A New Tale Band Makes 9/11 Tribute Song "The Twins" Free for Ceremonies and School Programs
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
- September Is Healthy Aging® Month Announces 2026 Theme: "Curiosity Has No Age Limit"